Literature DB >> 29427499

Is global elimination of HCV realistic?

Vincenza Calvaruso1, Salvatore Petta1, Antonio Craxì1.   

Abstract

The elimination of hepatitis C virus (HCV) has been made possible through the availability of new antiviral drugs which may now be administered to all patients with HCV infection, even those with decompensated cirrhosis. The goal of the World Health Organization (WHO) is to reduce the incidence of chronic hepatitis infection from the current 6-10 million to 0.9 million cases of chronic infections by 2030, and annual deaths from 1.4 million to fewer than 0.5 million. Achieving these targets will require full implementation of epidemiological knowledge of HCV infection, screening and testing practices and strategies to link HCV patients to care. This review will focus on the current state of knowledge in the epidemiology of HCV and what can be done to increase patient awareness and reduce the barriers to treatment. Furthermore, we will discuss the role of HCV clearance on the control of HCV-related outcomes.
© 2018 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  direct antiviral agents; linkage to care; screening

Mesh:

Substances:

Year:  2018        PMID: 29427499     DOI: 10.1111/liv.13668

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  16 in total

Review 1.  Implementing Treatment of Opioid-Use Disorder in Rural Settings: a Focus on HIV and Hepatitis C Prevention and Treatment.

Authors:  Jennifer R Havens; Sharon L Walsh; P Todd Korthuis; David A Fiellin
Journal:  Curr HIV/AIDS Rep       Date:  2018-08       Impact factor: 5.071

Review 2.  Hepatitis C virus vaccine design: focus on the humoral immune response.

Authors:  Daniel Sepulveda-Crespo; Salvador Resino; Isidoro Martinez
Journal:  J Biomed Sci       Date:  2020-07-06       Impact factor: 8.410

3.  The Massachusetts Hepatitis C Testing Cascade, 2014-2016.

Authors:  Quynh T Vo; Shauna Onofrey; Daniel Church; Kevin Cranston; Alfred DeMaria; R Monina Klevens
Journal:  Microbiol Insights       Date:  2019-06-21

4.  A novel point-of-care oral anti-HCV assay: Is it reliable for screening hepatitis C virus infection in the era of direct-acting antivirals?

Authors:  Rui-Feng Yang; Yan Liu; Cai-Yan Zhao; Ya-Xing Ding; Yu Chen; Ya-Dong Wang; Zhong-Ping Duan
Journal:  PLoS One       Date:  2019-02-12       Impact factor: 3.240

5.  HCV compliance and treatment success rates are higher with DAAs in structured HCV clinics compared to general hepatology clinics.

Authors:  Navdeep Chehl; Anurag Maheshwari; Hwan Yoo; Colleen Cook; Talan Zhang; Sara Brown; Paul J Thuluvath
Journal:  Medicine (Baltimore)       Date:  2019-07       Impact factor: 1.817

Review 6.  Structure-Based and Rational Design of a Hepatitis C Virus Vaccine.

Authors:  Johnathan D Guest; Brian G Pierce
Journal:  Viruses       Date:  2021-05-05       Impact factor: 5.818

Review 7.  A Focused Review on Recent Advances in the Diagnosis and Treatment of Viral Hepatitis.

Authors:  Wei Zhang; Mahmoud Aryan; Steve Qian; Roniel Cabrera; Xiuli Liu
Journal:  Gastroenterology Res       Date:  2021-06-19

Review 8.  Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.

Authors:  Thomas F Baumert; Thomas Berg; Joseph K Lim; David R Nelson
Journal:  Gastroenterology       Date:  2018-10-17       Impact factor: 33.883

Review 9.  Impact of direct-acting antiviral agents on the development of hepatocellular carcinoma: evidence and pathophysiological issues.

Authors:  Maria Tampaki; Spiros Savvanis; John Koskinas
Journal:  Ann Gastroenterol       Date:  2018-09-14

Review 10.  Discussion on critical points for a tailored therapy to cure hepatitis C virus infection.

Authors:  Nadia Marascio; Angela Quirino; Giorgio Settimo Barreca; Luisa Galati; Chiara Costa; Vincenzo Pisani; Maria Mazzitelli; Giovanni Matera; Maria Carla Liberto; Alfredo Focà; Carlo Torti
Journal:  Clin Mol Hepatol       Date:  2019-01-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.